DOCSLIB.ORG

GLEEVEC) in Patients with HIV Related Kaposi's Sarcoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GLEEVEC) in Patients with HIV Related Kaposi's Sarcoma AMC AIDS ASSOCIATED MALIGNANCY CLINICAL TRIALS CONSORTIUM AMC PROTOCOL #042 A Phase II Trial of Imatinib Mesylate (GLEEVEC) in Patients with HIV Related Kaposi's Sarcoma A Multi-Center Trial of the AIDS Malignancy Consortium Sponsored by: The National Cancer Institute Division of Cancer Treatment and Diagnosis Pharmaceutical Support Provided by: Novartis IND# 69,364 Protocol Chair: Henry B. Koon, M.D. Protocol Co-Chair: Ariela Noy, M.D. AMC # 042 (Version 7.0) 07/24/2007 NCI Version Date 07/24/07 i AMC PROTOCOL SIGNATURE PAGE I, , Principal Investigator at site , agree to conduct and follow this protocol: AMC Protocol #042 - A Phase II Trial of Imatinib Mesylate (GLEEVEC) in Patients with HIV Related Kaposi’s Sarcoma (Version 7.0, 07/24/2007), as written according to AMC, NCI and FDA guidelines. I understand that no deviations from the above protocol may be made without written permission from the Protocol Chair (s). _________________________________ _____________________ Signature Date (mm/dd/yyyy) AMC # 042 (Version 7.0) 07/24/2007 NCI Version Date 07/24/07 ii TABLE OF CONTENTS 1.0 Background/Rationale................................................................................................ 1 1.1 GLEEVEC® ...............................................................................................................................................1 1.2 BIOLOGIC/CORRELATIVE STUDIES..........................................................................................................11 1.3 STUDY DESIGN .......................................................................................................................................15 2.0 STUDY OBJECTIVES............................................................................................. 16 2.1 PRIMARY OBJECTIVES.............................................................................................................................16 2.2 SECONDARY OBJECTIVES........................................................................................................................16 3.0 PATIENT SELECTION .......................................................................................... 16 3.1 INCLUSION CRITERIA ..............................................................................................................................16 3.2 EXCLUSION CRITERIA .............................................................................................................................17 3.3 ENROLLMENT PROCEDURES....................................................................................................................18 4.0 CLINICAL AND LABORATORY EVALUATIONS........................................... 19 4.1 ELIGIBILITY/SCREENING .........................................................................................................................19 4.2 EVALUATIONS DURING TREATMENT ......................................................................................................21 4.3 EVALUATIONS AT THE TIME OF TREATMENT DISCONTINUATION ..........................................................22 4.4 FINAL EVALUATIONS/OFF DRUG, OFF STUDY ........................................................................................23 5.0 STUDY TREATMENT ............................................................................................ 24 5.1 DRUG REGIMENS, ADMINISTRATION AND DURATION ............................................................................24 5.2 DRUG ORDERS, TRANSFERS, RETURNS, AND ACCOUNTABILITY ............................................................24 5.3 DOSING ...................................................................................................................................................25 5.4 DOSE MODIFICATIONS FOR NON-HEMATOLOGICAL TOXICITY...............................................................25 5.5 DOSE MODIFICATIONS FOR HEMATOLOGICAL TOXICITY........................................................................27 5.6 CONCOMITANT THERAPY........................................................................................................................28 5.7 PERMITTED MEDICATIONS ......................................................................................................................29 5.8 PROHIBITED MEDICATIONS.....................................................................................................................30 5.9 PROHIBITED FOODS.................................................................................................................................30 5.10 TREATMENT COMPLIANCE......................................................................................................................30 6.0 REPORTING OF ADVERSE EVENTS................................................................. 31 6.1 CLASSIFICATION OF ADVERSE EVENTS BY SEVERITY & RELATIONSHIP TO STUDY DRUG ADMINISTRATION ...................................................................................................................................31 6.2 ADVERSE EVENT REPORTING TO NOVARTIS...........................................................................................32 6.3 ADVERSE EVENTS WITH COMMERCIAL AGENTS ....................................................................................33 7.0 CRITERIA FOR TREATMENT DISCONTINUATION..................................... 35 8.0 POST-TREATMENT EVALUATION AND EVALUATION AT EARLY DISCONTINUATION OF THERAPY................................................................... 36 9.0 EVALUATION OF RESPONSE............................................................................. 37 9.1 DEFINITION OF RESPONSE.......................................................................................................................37 10.0 RECORDS TO BE KEPT........................................................................................ 40 11.0 ROLE OF DATA MANAGEMENT ....................................................................... 41 11.1 CRF INSTRUCTIONS ................................................................................................................................41 11.2 DATA QUALITY.......................................................................................................................................41 AMC # 042 (Version 7.0) 07/24/2007 NCI Version Date 07/24/07 iii 12.0 STATISTICAL CONSIDERATIONS .................................................................... 42 12.1 SAMPLE SIZE ESTIMATION ......................................................................................................................42 12.2 STATISTICAL ANALYSIS PLAN ................................................................................................................42 12.3 AMC POLICY FOR MONITORING OF PHASE I AND PHASE II TRIALS........................................................43 13.0 ETHICAL AND REGULATORY CONSIDERATIONS ..................................... 44 13.1 INFORMED CONSENT...............................................................................................................................44 13.2 CHANGES TO THE PROTOCOL .................................................................................................................44 13.3 WOMEN AND MINORITIES ......................................................................................................................44 14.0 REFERENCES.......................................................................................................... 45 APPENDIX I: Schedule of Events............................................................................................ 47 APPENDIX II: Definition of AIDS Indicator Conditions....................................................... 48 APPENDIX III: Criteria for Acceptable AIDS Defining Events .......................................... 49 Appendix IV: Karnofsky Performance Scale........................................................................... 50 APPENDIX V: Recommended Staging Classification for Kaposi's Sarcoma ...................... 51 APPENDIX VI: Model Informed Consent.............................................................................. 52 APPENDIX VII: ACSR Informed Consent ............................................................................. 62 APPENDIX VIII: AIDS And Cancer Specimen Resource (ACSR) - Specimen Preparation & Shipping Instructions ........................................................................................... 65 APPENDIX IX: Punch Biopsy................................................................................................... 69 APPENDIX X: Punch Biopsy .................................................................................................... 72 APPENDIX XI: Cytokine Profiles Analysis............................................................................ 76 APPENDIX XII: Pharmacokinetic Analysis............................................................................ 79 APPENDIX XIII: HHV-8 Viral Load And Gene Expression................................................. 82 APPENDIX XIV: New York Heart Association Criteria ....................................................... 85 APPENDIX XV: Drugs Metabolized By CYP450 Isoenzymes 2D6 And 3A4....................... 86 APPENDIX XVI: Data Safety And Monitoring Plan.............................................................. 91 APPENDIX XVII: Novartis SAE Coversheet ........................................................................
Load more

Recommended publications
  • PROZAC Product Monograph Page 1 of 49 Table of Contents
    PRODUCT MONOGRAPH PrPROZAC® fluoxetine hydrochloride 10 mg and 20 mg Capsules Antidepressant / Antiobsessional / Antibulimic © Eli Lilly Canada Inc. Date of Revision: January, 25 Exchange Tower 2021 130 King Street West, Suite 900 PO Box 73 Toronto, Ontario M5X 1B1 1-888-545-5972 www.lilly.ca Submission Control No: 192639 PROZAC Product Monograph Page 1 of 49 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS .....................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................5 ADVERSE REACTIONS ...................................................................................................13 DRUG INTERACTIONS....................................................................................................22 DOSAGE AND ADMINISTRATION ................................................................................27 OVERDOSAGE..................................................................................................................28 ACTION AND CLINICAL PHARMACOLOGY ...............................................................30 STORAGE AND STABILITY............................................................................................32
    [Show full text]
  • The Myocardial Metabolic and Haemodynamic Effects of Perhexiline in I]Y Wvo and Nv Vitro Models
    THE MYOCARDIAL METABOLIC AND HAEMODYNAMIC EFFECTS OF PERHEXILINE IN I]Y WVO AND NV VITRO MODELS Steven Anthony Unger A Thesis submitted to The University of Adelaide as the requirement for the degree of Doctor of Philosophy The Cardiology Unit, North.Western Adelaide Health Service Department of Medicine, The University of Adelaide. September 2000 u TABLE OF CONTENTS Table of Contents ll Thesis Summary vlt Dcclaration ix Acknowledgments x CHAPTER 1: A LITERATURE REVIEW OF METABOLIC APPROACHES TO MYOCARDIAL ISCHAEMIA I 1.1 INTRODUCTION 2 7.2 CHRONIC MYOCARDIAL ISCHAEMIA 3 1.2.1 Epidemiology 3 1.2.2 Pathogenesis 4 1.3 CARDIAC METABOLISM 7 1.3.1 Overview offatty acid metabolism 8 1.3.1.1 Uptake and transport within the aqueous cytoplasm 8 1.3.1.2 Transport into mitochondria 9 1.3.1.3 B-oxidation l0 1.3.1.4 TCA cycle and electron transport chain 10 1.3.2 Regulation offatty acid metabolism 11 1.3.3 Oventiew of carbohydrate metabolism 13 1.3.4 Regulation of carbohydrate metabolism 14 ' L3.5 Substrate utilisation by the heart: the cost,in oxygen 16 1.3.6 Myocardial metabolism during ischaemia/reperfusion 18 1.3.7 The role offatty acid metabolites 22 1.4 MANAGEMENT OF CHRONIC MYOCARDIAL ISCHAEMIA 24 1.4.1 Medical therapy 24 alaaìf:a--.--nÁ 1.4. i. i i\iüa[es L+ 1.4.1.2 B-adrenoceptor antagonists 25 lrl 1.4.1.3 L-t1pe calcium antagonists 25 1.4.2 Revascularisation 26 1.4.2.1 Percutaneous transluminal coronary angioplasty 26 1.4.2.2 Coronary artery b¡pass surgery 28 I .4.2.3 Transmyocardial laser revascularisation 29 1.4.3 Limitations of current strategies 30 1.5 METABOLIC APPROACHES TO MYOCARDIAL ISCHAEMIA 32 1.5.1 Increasing glucose supply to the heart 35 1.5.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Drug-Induced Fatty Liver Disease
    789 Drug-induced fatty liver disease. , 2015; 14CONCISE (6): 789-806 REVIEW November-December, Vol. 14 No. 6, 2015: 789-806 Drug-induced fatty liver disease: An overview of pathogenesis and management Sanjaya K. Satapathy,* Vanessa Kuwajima,** Jeffrey Nadelson,** Omair Atiq,*** Arun J. Sanyal**** * Methodist University Hospital Transplant Institute, Division of Surgery, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA. ** Division of Gastroenterology and Hepatology, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA. *** University of Texas Southwestern, Dallas, Texas, USA. **** Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University Health System, Richmond, Virginia, USA. ABSTRACT Over the past decades, many drugs have been identified, that can potentially induce steatohepatitis in the predisposed individual. Classically this has been incriminated to amiodarone, perhexiline, and 4,4’-diethyla- minoethoxyhexestrol (DH), all of which have been found to independently induce the histologic picture of non-alcoholic steatohepatitis (NASH). Pathogenetic mechanisms of hepatotoxicity although still evolving, demonstrate that mitochondrial dysfunction, deranged ATP production and fatty acid catabolism likely play an important role. Drugs like steroid hormones can exacerbate the pathogenetic mechanisms that lead to NASH, and other drugs like tamoxifen, cisplatin and irenotecan have been shown to precipitate la- tent fatty liver as well. Further research aiming to elucidate
    [Show full text]
  • Drug-Induced Inhibition of Mitochondrial Fatty Acid Oxidation
    Drug-Induced Inhibition of Mitochondrial Fatty Acid Oxidation and Steatosis Julie Massart, Karima Begriche, Nelly Buron, Mathieu Porceddu, Annie Borgne-Sanchez, Bernard Fromenty To cite this version: Julie Massart, Karima Begriche, Nelly Buron, Mathieu Porceddu, Annie Borgne-Sanchez, et al.. Drug- Induced Inhibition of Mitochondrial Fatty Acid Oxidation and Steatosis. Current Pathobiology Re- ports, Springer, 2013, 1 (3), pp.147-157. 10.1007/s40139-013-0022-y. hal-00860237 HAL Id: hal-00860237 https://hal-univ-rennes1.archives-ouvertes.fr/hal-00860237 Submitted on 10 Sep 2013 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Heading for SpringerLink.com: Mitochondrial Dysfunction and Diseases (H Jaeschke, Section Editor) Drug-Induced Inhibition of Mitochondrial Fatty Acid Oxidation and Steatosis Julie Massart Karima Begriche Nelly Buron Mathieu Porceddu Annie Borgne-Sanchez Bernard Fromenty K. Begriche B. Fromenty () INSERM, U991, Université de Rennes 1 2, avenue du Professeur Léon Bernard 35043 Rennes Cedex, France e-mail: [email protected]
    [Show full text]
  • Abnormal Laboratory Results Therapeutic Drug Monitoring
    Abnormal laboratory results Therapeutic drug monitoring: which drugs, why, when and how to do it RA Ghiculescu, Senior Clinical Pharmacology Registrar, Department of Clinical Pharmacology, Princess Alexandra Hospital, Brisbane Summary Which drugs? Therapeutic drug monitoring of concentrations of When an effect, such as changes in blood pressure, pain or drugs in body fluids, usually plasma, can be used serum cholesterol is readily measured, the dose of a drug during treatment and for diagnostic purposes. The should be adjusted according to the response. Monitoring drug concentration is more useful when drugs are used to selection of drugs for therapeutic drug monitoring prevent an adverse outcome, for example, graft rejection or to is important as the concentrations of many avoid toxicity, as with aminoglycosides. A drug should satisfy drugs are not clearly related to their effects. For certain criteria to be suitable for therapeutic drug monitoring. selected drugs therapeutic drug monitoring aims Examples include: to enhance drug efficacy, reduce toxicity or assist n narrow target range with diagnosis. Despite its apparent advantages, n significant pharmacokinetic variability it has inherent limitations. Some large hospitals n a reasonable relationship between plasma concentrations have services which provide support with drug and clinical effects monitoring and interpretation of results. n established target concentration range Key words: pharmacokinetics. n availability of cost-effective drug assay. (Aust Prescr 2008;31:42–4) The most commonly monitored drugs are probably Introduction carbamazepine, valproate and digoxin. However, there is little The monitoring of therapeutic drugs involves measuring drug evidence that monitoring concentrations of anticonvulsants concentrations in plasma, serum or blood.
    [Show full text]
  • DOMASYS Standard
    New Zealand Data Sheet Optisulin – insulin glargine NEW ZEALAND DATA SHEET 1 PRODUCT NAME Optisulin 100 IU/mL solution for injection in 10 mL vials. Optisulin 100 IU/mL solution for injection in 3 mL cartridges. Optisulin SoloStar 100 IU/mL solution for injection in a 3 mL pre-filled pen. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Optisulin contains 100 IU/mL (3.6378 mg/mL) insulin glargine. Optisulin 100 IU/mL solution for injection in 10 mL vials - equivalent to 1000 IU. Optisulin 100 IU/mL solution for injection in 3 mL cartridges - equivalent to 300 IU. Optisulin SoloStar 100 IU/mL solution for injection in a 3 mL pre-filled pen – equivalent to 300 IU. Insulin glargine is produced by recombinant DNA technology in Escherichia coli. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Optisulin is a sterile solution of insulin glargine in vials and cartridges for use as an injection. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Optisulin is an insulin analogue indicated for once-daily subcutaneous administration in the treatment of type 1 or type 2 diabetes mellitus patients who require insulin for the control of optisulin-ccdsv20-dsv2-27jan21 Page 1 New Zealand Data Sheet Optisulin – insulin glargine hyperglycaemia. 4.2 DOSE AND METHOD OF ADMINISTRATION Dose Optisulin is an insulin analogue, equipotent to human insulin, with a peakless glucose lowering profile and a prolonged duration of action that permits once daily dosing. The desired blood glucose levels as well as the doses and timing of any antidiabetic medication, including Optisulin, must be determined and adjusted individually.
    [Show full text]
  • Repositioning Fda-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome
    Author Manuscript Published OnlineFirst on December 15, 2016; DOI: 10.1158/1535-7163.MCT-16-0588 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. REPOSITIONING FDA-APPROVED DRUGS IN COMBINATION WITH EPIGENETIC DRUGS TO REPROGRAM COLON CANCER EPIGENOME Noël J.-M. Raynal1,2, Elodie M. Da Costa2, Justin T. Lee1, Vazganush Gharibyan3, Saira Ahmed3, Hanghang Zhang1,Takahiro Sato1, Gabriel G. Malouf4, and Jean-Pierre J. Issa1 1Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, 3307 North Broad Street, Philadelphia, PA, 19140, USA. 2Département de pharmacologie, Université de Montréal and Sainte-Justine University Hospital Research Center, 3175, Chemin de la Côte-Sainte- Catherine, Montréal (Québec) H3T 1C5, Canada. 3Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. 4Department of Medical Oncology, Groupe Hospitalier Pitié-Salpêtrière, University Pierre and Marie Curie (Paris VI), Institut Universitaire de cancérologie, AP-HP, Paris, France. Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). Corresponding Author: Noël J.-M. Raynal, Département de Pharmacologie, Université de Montréal , Centre de recherche de l’Hôpital Sainte-Justine, 3175, Chemin de la Côte-Sainte-Catherine, Montréal (Québec), H3T 1C5, Canada. Phone : (514) 345-4931 ext. 6763. Email : [email protected] Running title: High-throughput screening for epigenetic drug combinations Key words: Drug repurposing, Drug combination, High-throughput drug screening, Epigenetic therapy The authors declare no potential conflicts of interest. 1 Downloaded from mct.aacrjournals.org on September 23, 2021.
    [Show full text]
  • Cyclosporiasis: an Update
    Cyclosporiasis: An Update Cirle Alcantara Warren, MD Corresponding author Epidemiology Cirle Alcantara Warren, MD Cyclosporiasis has been reported in three epidemiologic Center for Global Health, Division of Infectious Diseases and settings: sporadic cases among local residents in an International Health, University of Virginia School of Medicine, MR4 Building, Room 3134, Lane Road, Charlottesville, VA 22908, USA. endemic area, travelers to or expatriates in an endemic E-mail: [email protected] area, and food- or water-borne outbreaks in a nonendemic Current Infectious Disease Reports 2009, 11:108–112 area. In tropical and subtropical countries (especially Current Medicine Group LLC ISSN 1523-3847 Haiti, Guatemala, Peru, and Nepal) where C. cayetanen- Copyright © 2009 by Current Medicine Group LLC sis infection is endemic, attack rates appear higher in the nonimmune population (ie, travelers, expatriates, and immunocompromised individuals). Cyclosporiasis was a Cyclosporiasis is a food- and water-borne infection leading cause of persistent diarrhea among travelers to that affects healthy and immunocompromised indi- Nepal in spring and summer and continues to be reported viduals. Awareness of the disease has increased, and among travelers in Latin America and Southeast Asia outbreaks continue to be reported among vulnera- [8–10]. Almost half (14/29) the investigated Dutch attend- ble hosts and now among local residents in endemic ees of a scientifi c meeting of microbiologists held in 2001 areas. Advances in molecular techniques have in Indonesia had C. cayetanensis in stool, confi rmed by improved identifi cation of infection, but detecting microscopy and/or polymerase chain reaction (PCR), and food and water contamination remains diffi cult.
    [Show full text]
  • Inhibition of Mitochondrial Fatty Acid Oxidation in Drug-Induced Hepatic Steatosis*
    Liver Research 3 (2019) 157e169 Contents lists available at ScienceDirect Liver Research journal homepage: http://www.keaipublishing.com/en/journals/liver-research Review Article Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis* Bernard Fromenty INSERM, UMR 1241, Universite de Rennes 1, Rennes, France article info abstract Article history: Mitochondrial fatty acid oxidation (mtFAO) is a key metabolic pathway required for energy production in Received 17 April 2019 the liver, in particular during periods of fasting. One major consequence of drug-induced impairment of Received in revised form mtFAO is hepatic steatosis, which is characterized by an accumulation of triglycerides and other lipid 16 May 2019 species, such as acyl-carnitines. Actually, the severity of this liver lesion is dependent on the residual Accepted 14 June 2019 mitochondrial b-oxidation flux. Indeed, a severe inhibition of mtFAO leads to microvesicular steatosis, hypoglycemia and liver failure. In contrast, moderate impairment of mtFAO can cause macrovacuolar Keywords: steatosis, which is a benign lesion in the short term. Because some drugs can induce both microvesicular Drug-induced liver injury (DILI) Steatosis and macrovacuolar steatosis, it is surmised that severe mitochondrial dysfunction could be favored in Mitochondria some patients by non-genetic factors (e.g., high doses and polymedication), or genetic predispositions b-Oxidation involving genes that encode proteins playing directly or indirectly a role in the mtFAO pathway. Example Acetaminophen (APAP) of drugs inducing steatosis include acetaminophen (APAP), amiodarone, ibuprofen, linezolid, nucleoside Troglitazone reverse transcriptase inhibitors, such as stavudine and didanosine, perhexiline, tamoxifen, tetracyclines, troglitazone and valproic acid. Because several previous articles reviewed in depth the mechanism(s) whereby most of these drugs are able to inhibit mtFAO and induce steatosis, the present review is rather focused on APAP, linezolid and troglitazone.
    [Show full text]
  • Perhexiline Maleate in the Treatment of Fibrodysplasia Ossificans Progressiva
    Kitoh et al. Orphanet Journal of Rare Diseases 2013, 8:163 http://www.ojrd.com/content/8/1/163 RESEARCH Open Access Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trial Hiroshi Kitoh1*, Masataka Achiwa2, Hiroshi Kaneko1, Kenichi Mishima1, Masaki Matsushita1, Izumi Kadono3, John D Horowitz4, Benedetta C Sallustio4, Kinji Ohno5 and Naoki Ishiguro1 Abstract Background: Currently, there are no effective medical treatment options to prevent the formation of heterotopic bones in fibrodysplasia ossificans progressiva (FOP). By the drug repositioning strategy, we confirmed that perhexiline maleate (Pex) potentially ameliorates heterotopic ossification in model cells and mice. Here, we conducted a prospective study to assess the efficacy and safety of Pex in the treatment of FOP patients. Methods: FOP patients in this open-label single-center study were treated with Pex for a total of 12 months, and followed up for 12 consecutive months after medication discontinuation. The safety of the treatment was assessed regularly by physical and blood examinations. The efficacy of Pex for preventing heterotopic ossifications was evaluated by the presence of flare-ups, measurements of serum bone markers, and changes in the total bone volume calculated by the three-dimensional computed tomography (3D-CT) images. Results: Five patients with an average age of 23.4 years were enrolled. Within safe doses of Pex administration in each individual, there were no drug-induced adverse effects during the medication phase. Three patients showed no intense inflammatory reactions during the study period, while two patients had acute flare-ups around the hip joint without evidence of trauma during the medication phase.
    [Show full text]
  • Identification of Cyclospora and Isospora from Diarrheic Patients in the Philippines
    Philippine Journal of Science RESEARCH NOTE 137 (1): 11-15, June 2008 ISSN 0031 - 7683 Identification of Cyclospora and Isospora from Diarrheic Patients in the Philippines Corazon C. Buerano1,2, Catherine B. Lago1, Ronald R. Matias1, Blanquita B. de Guzman1, Shinji Izumiyama3, Kenji Yagita3, and Filipinas F. Natividad1* 1Research and Biotechnology Division, St. Luke’s Medical Center 279 E. Rodriguez Sr. Ave., Quezon City 1102, Philippines 2Institute of Biology, University of the Philippines Diliman, Quezon City 1101, Philippines 3Department of Parasitology, National Institute of Infectious Diseases Toyama 1-23-1, Shinjuku-ku, Tokyo 162-8640, Japan In recent years, Cyclospora cayetanensis and Isospora belli have been recognized as causative organisms in cases of chronic diarrhea. The aim of this study was undertaken to determine the prevalence of enteric protozoa among diarrhea patients in the Philippines. Stools were collected and from 3456 samples examined, only one sample each was found positive for oocysts of Cyclospora cayetanensis and Isospora belli. Identification was based on autofluorescence of the oocysts with a 365 nm ultraviolet excitation filter. Both samples were obtained from male patients (18 and 73 years old, respectively) living in Iloilo province in the western islands of Visayas, Philippines. Both patients obtained their drinking water from deep wells. The identification of these two emerging pathogens, which are easily overlooked by less-trained technical staff, highlights the increasing awareness and technical capability on detecting these parasites in the Philippines. Key Words: Cyclospora, Isospora, enteric protozoa, diarrhea INTRODUCTION in tropical areas of south America and southeast Asia (Wittner et al. 1993), and has also been associated with Both Cyclospora and Isospora belongs to family diarrhea outbreaks in mental wards and day care centers Eimeridae, subphylum apicomplexa, which are (Marshall et al.
    [Show full text]